Mai Capital Management Horizon Therapeutics Public LTD CO Transaction History

Mai Capital Management

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$98.98 - $115.74 $791 - $925	-8 Reduced 0.16%	5,124 $592,000
Q2 2023 Aug 02, 2023	SELL	$96.34 - $112.38 $963 - $1,123	-10 Reduced 0.19%	5,132 $527,000
Q1 2023 May 10, 2023	SELL	$107.32 - $113.5 $28,332 - $29,964	-264 Reduced 4.88%	5,142 $561,000
Q4 2022 Feb 09, 2023	SELL	$62.39 - $113.8 $28,325 - $51,665	-454 Reduced 7.75%	5,406 $615,000
Q3 2022 Nov 15, 2022	SELL	$58.92 - $84.67 $779,393 - $1.12 Million	-13,228 Reduced 69.3%	5,860 $363,000
Q2 2022 Jul 19, 2022	SELL	$79.4 - $116.36 $144,984 - $212,473	-1,826 Reduced 8.73%	19,088 $1.52 Million
Q1 2022 May 10, 2022	SELL	$86.42 - $109.81 $91,950 - $116,837	-1,064 Reduced 4.84%	20,914 $2.2 Million
Q4 2021 Feb 11, 2022	BUY	$98.56 - $119.91 $689 - $839	7 Added 0.03%	21,978 $2.37 Million
Q4 2020 Feb 16, 2021	SELL	$67.0 - $84.39 $43,818 - $55,191	-654 Reduced 2.89%	21,971 $1.61 Million
Q3 2020 Oct 26, 2020	BUY	$55.23 - $79.93 $159,338 - $230,598	2,885 Added 14.61%	22,625 $1.76 Million
Q2 2020 Jul 27, 2020	BUY	$30.2 - $56.98 $596,148 - $1.12 Million	19,740 New	19,740 $1.1 Million

2.07M

20K

Ticker HZNP
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 230,384,000
Description
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines ...

Get notified when there are updates to the investment portfolio of Mai Capital Management, based on Form 13F filings with the SEC.

Stay updated on Mai Capital Management with notifications on news.